Welcome to our dedicated page for Unity Btech news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Btech stock.
Unity Biotechnology, Inc. (historically Nasdaq: UBX, now quoted over‑the‑counter as UNBX) has generated a stream of news centered on its efforts to develop senolytic and senescence‑modulating therapeutics for age‑related diseases, particularly in ophthalmology. Company press releases emphasize UBX1325, an investigational BCL‑xL inhibitor being studied in diabetic macular edema (DME), and the broader scientific rationale for targeting senescent cells in retinal disease.
News coverage for UBX includes clinical trial milestones from the Phase 2 BEHOLD and Phase 2b ASPIRE studies in DME, where Unity has reported statistically significant and clinically meaningful improvements in vision in BEHOLD and non‑inferior visual acuity gains versus aflibercept at most time points in ASPIRE, along with a favorable safety and tolerability profile. Additional articles highlight scientific recognition, such as publication of BEHOLD results in NEJM Evidence and presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meetings.
Corporate updates are another major theme. Recent releases describe Unity’s revised operating plans, substantial reductions in force, and a strategic review to explore alternatives for advancing UBX1325 and other assets while reducing operational cash burn. Governance and leadership developments, including board appointments and executive hires in ophthalmology and clinical development, have also been featured.
Regulatory and financial disclosures reported in Unity’s news flow include quarterly and annual financial results, cash runway commentary, and communications about Nasdaq listing compliance, delisting actions, and the transition of trading to the OTC Pink Marketplace. More recent filings and related announcements focus on Unity’s Plan of Dissolution under Delaware law, the scheduling of a special stockholder meeting to vote on liquidation and dissolution, and the company’s expectation, as disclosed in its proxy statement, that there may be no amounts available for distribution to stockholders.
Investors and observers following UBX news can therefore track both the historical development of its senolytic ophthalmology programs and the subsequent shift toward asset monetization, delisting, and planned corporate dissolution.
UNITY Biotechnology announced results from the Phase 2 ENVISION study of UBX1325 for wet age-related macular degeneration (AMD) on March 27, 2023. UBX1325 maintained visual acuity in patients over 24 weeks, with less than one letter mean decrease from baseline. However, it did not achieve non-inferiority compared to anti-VEGF control, which saw an unexpected gain of 3.5 letters. Notably, 52% of UBX1325 patients did not need anti-VEGF treatments during the study. The company plans to release 48-week data from the BEHOLD DME study in April and initiate a Phase 2b study in DME in the latter half of 2023.
UNITY Biotechnology, Inc. (UBX) reported its financial results for Q4 and FY 2022, with a cash position of $94.8 million, sufficient to fund operations into Q1 2024. Achievements included positive 24-week data from the Phase 2 BEHOLD study for UBX1325 and completion of enrollment in the Phase 2 ENVISION study for age-related macular degeneration. The operating loss for 2022 was $57.6 million, slightly up from $56.7 million in 2021. R&D expenses decreased by $1.5 million YoY, reflecting cost reductions, despite an increase in direct expenses for UBX1325. The upcoming milestone includes 24-week data from ENVISION expected by the end of March 2023.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 – UNITY Biotechnology, a biotechnology firm focused on therapeutics to address aging-related diseases, announced its participation in the Cowen 43rd Annual Health Care Conference. The event is scheduled for March 7, 2023, at 9:50 AM ET, featuring updates from the Company’s Management and one-on-one investor meetings. The presentation will be accessible via webcast and also through the ‘Investors and Media’ section on their website. UNITY's mission includes developing treatments to eliminate or modulate senescent cells, specifically targeting age-related ophthalmologic and neurologic diseases.
UNITY Biotechnology [NASDAQ: UBX] has scheduled a corporate update and one-on-one investor meetings at the SVB Securities Global Biopharma Conference on February 15, 2023, at 11:20 AM ET. The company focuses on developing therapeutics to address diseases of aging, particularly targeting age-related ophthalmologic and neurologic diseases by eliminating or modulating senescent cells. The presentation will be accessible via webcast and can also be found on their website under the 'Investors and Media' section.
UNITY Biotechnology, Inc. (NASDAQ: UBX) announced an investor call scheduled for February 14, 2023, at 7:00 a.m. PT, featuring retinal expert Dr. Robert B. Bhisitkul. The call will discuss data from the Phase 2 BEHOLD study on UBX1325 for diabetic macular edema and updates on the ENVISION study focused on wet age-related macular degeneration (AMD). Notably, complete 16- and 24-week safety and efficacy data from the ENVISION study are expected in Q1 2023. A live Q&A will follow the presentation. Interested investors can access the webcast on the company’s website or view it later in the 'Events & Presentations' section.
UNITY Biotechnology, Inc. (NASDAQ: UBX), a biotechnology firm focused on therapeutics that address aging-related diseases, disclosed that from January 3 to January 17, 2023, its Board's Compensation Committee granted a stock-based award of 900 shares to a new employee. This grant was made under the amended 2020 Employment Inducement Incentive Plan, aimed at attracting new talent in compliance with Nasdaq Rule 5635(c)(4). UNITY is currently working on therapies to target and eliminate senescent cells, with a focus on age-related ophthalmologic and neurologic diseases.
UNITY Biotechnology reported positive results from the Phase 2 BEHOLD study of UBX1325 for treating Diabetic Macular Edema, showing a 7.6-letter improvement in BCVA after 24 weeks. The drug demonstrated a favorable safety profile. UNITY's financial position improved, with cash and equivalents totalling $103.9 million as of September 30, 2022. This funding is expected to support operations into Q1 2024. A reduction in operating loss to $13.1 million, down from $14.8 million, reflects enhanced efficiency in operations.
UNITY Biotechnology announced positive results from the Phase 2 BEHOLD study of UBX1325 in diabetic macular edema (DME), showing a significant improvement in Best Corrected Visual Acuity (BCVA) of +7.6 letters compared to sham treatment after 24 weeks (p=0.0084). UBX1325 also stabilized retinal structure as measured by central subfield thickness. Notably, 59.4% of treated patients did not require anti-VEGF rescue therapy after 6 months. Following these promising outcomes, the company plans to initiate a pivotal study in DME in the second half of 2023.
UNITY Biotechnology (Nasdaq:UBX) is set to host a program update on its lead therapeutic UBX1325 for age-related diseases on November 1, 2022. The session features retinal expert Dr. Arshad M. Khanani, highlighting advancements in treatments aimed at senescent cells to combat aging-related conditions. This update signifies a pivotal moment in the company’s ongoing efforts to revolutionize therapies for ophthalmologic and neurological diseases.
UNITY Biotechnology (Nasdaq: UBX) has announced a 1-for-10 reverse stock split effective October 19, 2022, at 5:00 PM ET, with trading on a split-adjusted basis starting October 20, 2022. This action aims to ensure compliance with Nasdaq's minimum bid price requirement. The reverse split was approved by stockholders on October 18, 2022, and will convert every 10 shares into one. Stockholders entitled to fractional shares will receive cash payment. For further details, refer to the SEC filings and the company's website.